Advertisement

Current Heart Failure Reports

, Volume 15, Issue 5, pp 281–286 | Cite as

Clinical Implications of Serum Biomarkers of Cardiac Stress in Aortic Stenosis

  • Nimesh Patel
  • Dharam J. KumbhaniEmail author
Biomarkers of Heart Failure (W Tang and J Grodin, Section Editors)
  • 186 Downloads
Part of the following topical collections:
  1. Topical Collection on Biomarkers of Heart Failure

Abstract

Purpose of Review

The purpose of this review is to outline the relationship between serum biomarkers of cardiac stress and the pathophysiologic progression of aortic stenosis, to identify studies exploring the utility of biomarkers in the risk stratification and management of patients with aortic stenosis, and to highlight the biomarkers most practical to management of patients with aortic stenosis.

Recent Findings

Several biomarkers have been identified that reflect various aspects of the pathogenesis of calcific aortic stenosis, subsequent hemodynamic obstruction leading to myocardial remodeling, oxidative stress and injury, and concomitant systemic inflammation. These markers are associated with adverse outcomes in aortic stenosis and offer incremental value in risk prediction over traditional clinical assessment for aortic stenosis. NTproBNP and troponin are the most rigorously studied serum biomarkers in aortic stenosis, and only NTproBNP is currently reflected in any major guideline on aortic stenosis management.

Summary

Serum biomarkers show promise in guiding management of aortic stenosis, but still require significant prospective investigation before they can be incorporated in major guidelines.

Keywords

Serum biomarkers Heart failure Aortic stenosis 

Notes

Compliance with Ethical Standards

Conflict of Interest

Nimesh Patel declares no potential conflicts of interest.

Dharam J. Kumbhani reports honoraria from the American College of Cardiology.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Lindman BR, Clavel MA, Mathieu P, et al. Calcific aortic stenosis. Nat Rev Dis Primers. 2016;2:16006.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:2440–92.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Otto CM, Kumbhani DJ, Alexander KP, Calhoon JH, Desai MY, Kaul S, et al. 2017 ACC expert consensus decision pathway for transcatheter aortic valve replacement in the management of adults with aortic stenosis: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2017;69:1313–46.CrossRefPubMedGoogle Scholar
  4. 4.
    Rosenhek R, Klaar U, Schemper M, Scholten C, Heger M, Gabriel H, et al. Mild and moderate aortic stenosis. Natural history and risk stratification by echocardiography. Eur Heart J. 2004;25:199–205.CrossRefPubMedGoogle Scholar
  5. 5.
    Otto CM, Burwash IG, Legget ME, Munt BI, Fujioka M, Healy NL, et al. Prospective study of asymptomatic valvular aortic stenosis: clinical, echocardiographic, and exercise predictors of outcome. Circulation. 1997;95:2262–70.CrossRefPubMedGoogle Scholar
  6. 6.
    Joint Task Force on the Management of Valvular Heart Disease of the European Society of C, European Association for Cardio-Thoracic S, Vahanian A, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;33:2451–96.CrossRefGoogle Scholar
  7. 7.
    Baumgartner H, Falk V, Bax JJ, de Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–91.CrossRefPubMedGoogle Scholar
  8. 8.
    • Redfors B, Furer A, Lindman BR, Burkhoff D, Marquis-Gravel G, Francese DP, et al. Biomarkers in aortic stenosis: a systematic review. Structural Heart. 2017;1:18–30. A detailed systematic review of the biomarkers of cardiac stress that have been studied in patients with aortic stenosis.CrossRefGoogle Scholar
  9. 9.
    • Lindman BR, Breyley JG, Schilling JD, Vatterott AM, Zajarias A, Maniar HS, et al. Prognostic utility of novel biomarkers of cardiovascular stress in patients with aortic stenosis undergoing valve replacement. Heart. 2015;101:1382–8. A prospective registry study that assesses the utility of multiple biomarkers of cardiovascular stress in predicting mortality after aortic vale replacement independent of clinical risk factors.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Steadman CD, Ray S, Ng LL, McCann GP. Natriuretic peptides in common valvular heart disease. J Am Coll Cardiol. 2010;55:2034–48.CrossRefPubMedGoogle Scholar
  11. 11.
    Bergler-Klein J, Klaar U, Heger M, Rosenhek R, Mundigler G, Gabriel H, et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation. 2004;109:2302–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Lim P, Monin JL, Monchi M, et al. Predictors of outcome in patients with severe aortic stenosis and normal left ventricular function: role of B-type natriuretic peptide. Eur Heart J. 2004;25:2048–53.CrossRefPubMedGoogle Scholar
  13. 13.
    Van Pelt NC, Kerr AJ, Legget ME, et al. Increased B-type natriuretic peptide is associated with an abnormal blood pressure response to exercise in asymptomatic aortic stenosis. Int J Cardiol. 2008;127:313–20.CrossRefPubMedGoogle Scholar
  14. 14.
    Clavel MA, Malouf J, Michelena HI, Suri RM, Jaffe AS, Mahoney DW, et al. B-type natriuretic peptide clinical activation in aortic stenosis: impact on long-term survival. J Am Coll Cardiol. 2014;63:2016–25.CrossRefPubMedGoogle Scholar
  15. 15.
    Abramowitz Y, Chakravarty T, Jilaihawi H, Lee C, Cox J, Sharma RP, et al. Impact of preprocedural B-type natriuretic peptide levels on the outcomes after transcatheter aortic valve implantation. Am J Cardiol. 2015;116:1904–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Farre N, Gomez M, Molina L, et al. Prognostic value of NT-proBNP and an adapted monin score in patients with asymptomatic aortic stenosis. Rev Esp Cardiol (Engl Ed). 2014;67:52–7.CrossRefGoogle Scholar
  17. 17.
    de Lemos JA. Increasingly sensitive assays for cardiac troponins: a review. JAMA. 2013;309:2262–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Chin CW, Shah AS, McAllister DA, et al. High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis. Eur Heart J. 2014;35:2312–21.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kohler WM, Freitag-Wolf S, Lambers M, et al. Preprocedural but not periprocedural high-sensitive troponin T levels predict outcome in patients undergoing transcatheter aortic valve implantation. Cardiovasc Ther. 2016;34:385–96.CrossRefPubMedGoogle Scholar
  20. 20.
    Solberg OG, Ueland T, Wergeland R, et al. High-sensitive troponin T and N-terminal-brain-natriuretic-peptide predict outcome in symptomatic aortic stenosis. Scand Cardiovasc J. 2012;46:278–85.CrossRefPubMedGoogle Scholar
  21. 21.
    Iida M, Yamazaki M, Honjo H, Kodama I, Kamiya K. Predictive value of heart-type fatty acid-binding protein for left ventricular remodelling and clinical outcome of hypertensive patients with mild-to-moderate aortic valve diseases. J Hum Hypertens. 2007;21:551–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Yarbrough WM, Mukherjee R, Ikonomidis JS, Zile MR, Spinale FG. Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications. J Thorac Cardiovasc Surg. 2012;143:656–64.CrossRefPubMedGoogle Scholar
  23. 23.
    Martos R, Baugh J, Ledwidge M, et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation. 2007;115:888–95.CrossRefPubMedGoogle Scholar
  24. 24.
    Kapelouzou A, Tsourelis L, Kaklamanis L, Degiannis D, Kogerakis N, Cokkinos DV. Serum and tissue biomarkers in aortic stenosis. Glob Cardiol Sci Pract. 2015;2015:49.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Villar AV, Llano M, Cobo M, et al. Gender differences of echocardiographic and gene expression patterns in human pressure overload left ventricular hypertrophy. J Mol Cell Cardiol. 2009;46:526–35.CrossRefPubMedGoogle Scholar
  26. 26.
    Pascual-Figal DA, Januzzi JL. The biology of ST2: the international ST2 consensus panel. Am J Cardiol. 2015;115:3B–7B.CrossRefPubMedGoogle Scholar
  27. 27.
    Lancellotti P, Dulgheru R, Magne J, et al. Elevated plasma soluble ST2 is associated with heart failure symptoms and outcome in aortic stenosis. PLoS One. 2015;10:e0138940.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110:3121–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Baldenhofer G, Zhang K, Spethmann S, et al. Galectin-3 predicts short- and long-term outcome in patients undergoing transcatheter aortic valve implantation (TAVI). Int J Cardiol. 2014;177:912–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Mohty D, Pibarot P, Despres JP, et al. Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol. 2008;28:187–93.CrossRefPubMedGoogle Scholar
  31. 31.
    Mahmut A, Boulanger MC, El Husseini D, et al. Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization. J Am Coll Cardiol. 2014;63:460–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Capoulade R, Mahmut A, Tastet L, et al. Impact of plasma Lp-PLA2 activity on the progression of aortic stenosis: the PROGRESSA study. JACC Cardiovasc Imaging. 2015;8:26–33.CrossRefPubMedGoogle Scholar
  33. 33.
    Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844–53.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Capoulade R, Chan KL, Yeang C, et al. Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. J Am Coll Cardiol. 2015;66:1236–46.CrossRefPubMedGoogle Scholar
  35. 35.
    Capoulade R, Magne J, Dulgheru R, et al. Prognostic value of plasma B-type natriuretic peptide levels after exercise in patients with severe asymptomatic aortic stenosis. Heart. 2014;100:1606–12.CrossRefPubMedGoogle Scholar
  36. 36.
    Antonini-Canterin F, Popescu BA, Popescu AC, et al. Heart failure in patients with aortic stenosis: clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement. Int J Cardiol. 2008;128:406–12.CrossRefPubMedGoogle Scholar
  37. 37.
    Krau NC, Lunstedt NS, Freitag-Wolf S, et al. Elevated growth differentiation factor 15 levels predict outcome in patients undergoing transcatheter aortic valve implantation. Eur J Heart Fail. 2015;17:945–55.CrossRefPubMedGoogle Scholar
  38. 38.
    Schafer MJ, Atkinson EJ, Vanderboom PM, et al. Quantification of GDF11 and myostatin in human aging and cardiovascular disease. Cell Metab. 2016;23:1207–15.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Aung N, Dworakowski R, Byrne J, et al. Progressive rise in red cell distribution width is associated with poor outcome after transcatheter aortic valve implantation. Heart. 2013;99:1261–6.CrossRefPubMedGoogle Scholar
  40. 40.
    Parenica J, Nemec P, Tomandl J, et al. Prognostic utility of biomarkers in predicting of one-year outcomes in patients with aortic stenosis treated with transcatheter or surgical aortic valve implantation. PLoS One. 2012;7:e48851.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the valve academic research consortium. J Am Coll Cardiol. 2011;57:253–69.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of CardiologyUniversity of Texas Southwestern Medical CenterDallasUSA

Personalised recommendations